Reduction of tumour blood flow with KB-R8498 potentiates the response of tumours to hyperthermia.

Abstract

The anti-tumour activity and the effect on tumour and normal tissue perfusion of a newly discovered anticancer agent, KB-R8498 (Kanebo Ltd., Osaka, Japan), were investigated in FSa II tumours of C3H mice. The tumour perfusion, as measured by the 86Rb-uptake method, markedly decreased with relatively little change in the normal tissue perfusion after an i.v. injection of KB-R8498. Furthermore, the drug potentiated the effect of hyperthermia at 42.5 degrees C for 60 min to suppress the tumour growth. The results suggest that the preferential reduction in tumour blood flow relative to normal tissue blood flow by KB-R8498 may be exploited to enhance the anti-tumour effect of hyperthermia.

• Authors: A Shakil, A Ogawa, R J Griffin, C W Song
• Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (Int J Hyperthermia) 1999 Jan-Feb Vol. 15 Issue 1 Pg. 1-6 ISSN: 0265-6736 [Print] England
• PMID: 10193752 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• KB-R8498
• Piperazines
• Quinazolines

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Combined Modality Therapy
• Dose-Response Relationship, Drug
• Hyperthermia, Induced
• Mice
• Mice, Inbred C3H
• Neoplasms, Experimental (blood supply, pathology, therapy)
• Piperazines (therapeutic use)
• Quinazolines (therapeutic use)